Merck & Co. Faces Q3 Earnings Downgrade: What Investors Need to Know
Leerink Partners has cast a shadow on Merck & Co.’s third-quarter 2025 earnings outlook, signaling a notable adjustment in their financial projections for the pharmaceutical giant. This…